Purpose The aim of this study was to investigate the usefulness of breast-specific gamma imaging (BSGI) with dualphase imaging for increasing diagnostic performance and interpreter confidence. Methods We studied 76 consecutive patients (mean age: 49.3 years, range: 33-61 years) who received 925 MBq (25 mCi) 99m Tc-sestamibi intravenously. Craniocaudal and mediolateral oblique planar images were acquired for all patients. Delayed images were obtained from all patients 1 h after tracer injection, except for patients with no definite abnormal uptake. All images were classified into four categories: group 1 (definite negative) 0 no definite abnormal uptake; group 2 (possible negative) 0 symmetrically diffuse and amorphous uptake; group 3 (possible positive) 0 asymmetrically mild and nodular uptake; group 4 (definite positive) 0 asymmetrically intense and nodular uptake. To evaluate diagnostic performance, the BSGI studies were classified as positive (group 3 or 4) or negative (group 1 or 2) for malignancy according to a visual analysis. The final diagnoses were derived from histopathological confirmation and/or imaging follow-up after at least 6 months (range: 6-14 months) by both ultrasonography and mammography. Results The patients' ages ranged from 33 to 61 years, with an average of 49.3 years. Thirteen patients were diagnosed with malignancy, and 63 patients were diagnosed as negative for malignancy. Using early images, 43 patients were classified as group 1, 12 as group 2, 10 as group 3 and 11 as group 4. Based on early images, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of BSGI were 77 %, 83 %, 48 %, 95 % and 82 %, respectively. Dual-phase BSGI had a sensitivity, specificity, PPV, NPV and accuracy of 69 %, 95 %, 75 %, 94 % and 91 %, respectively. The BSGI specificity was significantly higher with dual-phase imaging than with single-phase imaging (p00.0078), but the sensitivity did not differ significantly (p01.0). Based on dual-phase imaging, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of BSGI for the evaluation of US BI-RADS 4 lesions were 60 %, 86 %, 67 %, 83 % and 78 %, respectively. Conclusion Dual-phase imaging in BSGI showed good diagnostic performance and would be useful for increasing interpreter diagnostic confidence, with higher specificity, positive predictive value and accuracy for breast cancer screening as well as the differential diagnosis of breast disease compared with single-phase imaging.
Introduction
Mammography has been shown to be effective in the diagnosis of breast cancer, both as a screening examination and when faced with clinical suspicion of the disease. Although mammography is the most commonly used procedure for breast cancer diagnosis, it is an imperfect examination, with a sensitivity of 70-90 %, which may be reduced in patients with dense breast tissue, implants, severe dysplastic disease or significant architectural distortion following breast surgery or radiation therapy [1] [2] [3] [4] [5] [6] [7] .
Furthermore, mammography is a relatively nonspecific diagnostic technique, which often does not distinguish malignant lesions from benign conditions. It has a high false-positive rate (60-80 %), which leads to an elevated number of biopsies being performed on benign lesions [6, 7] . Therefore, adjunct methods are needed to improve breast cancer detection and the differentiation of benign and malignant lesions.
Breast-specific gamma imaging (BSGI), a molecular breast-imaging technique, is a physiologic approach to breast imaging using a high-resolution gamma camera. BSGI is used as a complementary procedure to help detect breast cancer when more information is needed after questionable radiological examinations [8] [9] [10] .
Despite improved camera resolution and metabolic imaging using 99m Tc sestamibi, benign lesions taking up sestamibi and physiologic activity mimicking nodules on BSGI are not unusual, and these often result in ambiguous conclusions.
We hypothesized that imaging at two time points would be helpful to differentiate malignant lesions from benign conditions, which can result in false-positive results on BSGI. The aim of this study was to investigate the usefulness of BSGI with dual-phase imaging for increasing diagnostic performance and interpreter confidence.
Materials and Methods

Patients
Seventy-six female patients were enrolled in the study. The patients' ages ranged from 33 to 61 years, with an average of 49.3 years. All of the patients received a conventional imaging examination (ultrasonography and/or mammography and/or MRI) and BSGI. The clinical indications for BSGI included the following: a palpable lesion, a diagnosis of multicentricity and/or multifocality in women with biopsy-proven cancer, screening of women for breast cancer, and determining the appropriate biopsy site in patients with multiple lesions detected by a mammogram and/or ultrasound.
Histopathological confirmation was performed for 35 patients, and imaging follow-up studies were performed for 41 patients prior to the final diagnosis. The biopsy results were classified as malignancy [invasive ductal carcinoma (IDC), ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)] or benign conditions [fibrocystic change (FCC), fibroadenoma, intraductal papilloma or hamartoma].
Imaging Procedure
BSGI Each patient was given 925 MBq (25 mCi) of 99m Tcsestamibi intravenously as a single dose in the arm. We used a dedicated high-resolution, small field of view gamma camera optimized to perform BSGI (Dilon 6800 Gamma Camera, Dilon Technologies, Newport News, VA, USA). A breast-specific gamma camera was used to acquire images while the patient was seated in a position similar to the mammogram position, and the breast was lightly compressed. Craniocaudal and mediolateral oblique planar images were acquired right after injection for all patients. More than 100,000 counts were acquired for craniocaudal imaging and more than 120,000 counts for mediolateral oblique imaging using a low-energy general-purpose collimator. The matrix size was 80×80, and the energy window was ±10 % centered on 140 keV for 99m Tc-sestamibi. Delayed images were obtained 1 h after tracer injection, with the same acquisition time as early imaging.
Ultrasonography (US) US was performed using linear highfrequency transducers with 5-12 MHz broadband width (iU22 xMATRIX ultrasound system, Philips Medical Systems, Bothwell, WA, USA). Imaging data were analyzed according to the Breast Imaging Reporting and Data System (BI-RADS) lexicon.
Image Analysis
The uptake pattern of 99m Tc-sestambi was visually assessed by an experienced nuclear medicine physician according to uptake on the early images and the presence or absence of washout on the delayed images.
All images were classified into four categories by early images: group 1 (definite negative) 0 no definite abnormal uptake; group 2 (possible negative) 0 symmetrically diffuse and amorphous uptake; group 3 (possible positive) 0 asymmetrically mild and nodular uptake; group 4 (definite positive) 0 asymmetrically intense and nodular uptake (Fig. 1) . To assess the diagnostic performance of BSGI using early images, a negative result for malignancy was defined as no definite abnormal uptake or symmetrically diffuse and amorphous uptake (groups 1 and 2), and a positive result for malignancy was defined as asymmetrically mild or intense nodular uptake in breast tissue in at least one view (groups 3 and 4). For the assessment of the diagnostic performance of dual-phase BSGI, patients in groups 3 and 4 with washout on the delayed image were classified as negative, and patients in groups 3 and 4 with persistent tracer uptake on delayed images were classified as positive for malignancy.
Reference Standard
The final diagnoses (nonmalignancy or malignancy) were derived from biopsies (fine-needle aspiration, core needle or excision biopsy), which were performed within 1 month of BSGI, and/or imaging follow-up studies, which were performed after at least 6 months (range: 6-14 months) by both ultrasonography and mammography. Lesions with increased size and showing a distinct malignant pattern on the followup images were considered suspicious for malignancy, and a biopsy was performed. In contrast, lesions showing a benign nature and unchanged size over the 6-month follow-up period were regarded as benign.
Data Analysis
Abnormalities on BSGI were correlated with the clinical, pathological and radiological findings. Statistical analyses were performed using Medcalc version 12.0.0 (MedCalc Software, Mariakerke, Belgium). Diagnostic performance was evaluated based on the calculated sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy. The McNemar test was used to compare sensitivity and specificity. A P value less than 0.05 was considered to be statistically significant.
Results
Patient Characteristics
Thirteen patients were diagnosed with a malignancy, and 63 patients were diagnosed as negative for malignancy. There were a total of 16 pathologically confirmed cancers in 13 patients. These 16 malignant lesions included IDC (n010), DCIS (n05) and LCIS (n01). Three patients had two separate cancer foci; one patient had two foci of IDC, and two patients had both DCIS and IDC. The 30 pathologically confirmed benign lesions included fibrocystic changes (n0 19), fibroadenomas (n05), intraductal papillomas (n04), mastitis (n01), and a hamartoma (n01).
End Results of Each Scintigraphic Pattern
Using early images, 43 patients were classified as group 1, 12 as group 2, 10 as group 3 and 11 as group 4. The histopathologic diagnoses of the enrolled patient population in relation to the BSGI uptake pattern are shown in Table 1 .
One patient showed tracer washout on the delayed image in group 4 (1/11, 9 %), and this patient was identified as having three benign conditions (2 FCCs and 1 intraductal papilloma) following a biopsy (Fig. 2) . In this patient, the lesion that showed washout of the tracer on the delayed images was pathologically confirmed as FCC. The other ten patients of group 4 showed persistent tracer uptake (Fig. 3 ). Nine of these ten patients (9/10, 90 %) were pathologically confirmed as having breast cancer, and the remaining one patient was diagnosed as negative for malignancy by an imaging follow-up (ultrasound and mammogram) examination at approximately 7 months.
Delayed tracer washout was found in nine patients in group 3 (9/10, 90 %) (Fig. 4) . Eight of these nine patients were diagnosed as negative for malignancy (8/9, 89 %), and the remaining one patient was pathologically confirmed as having high-grade DCIS. One patient in group 3 had persistent tracer uptake on delayed images and was diagnosed with a hamartoma.
Six patients in group 2 showed tracer washout on delayed images (6/12, 50 %). Of these six patients, five were diagnosed as negative for malignancy (5/6, 83 %), and the remaining patient had two malignant lesions (low-grade IDC and low-grade DCIS).
Group 1 included 43 patients. One DCIS patient and one LCIS patient were included in group 1.
False-Positive and False-Negative Results
The false-positive results of single-and dual-phase BSGI are shown in Table 2 . There were 11 false-positive results in single-phase BSGI. Eight of nine patients categorized as BSGI group 3 showed tracer washout on delayed images (8/9, 89 %), and their diagnoses were changed from malignant to benign. Three patients (patients 9, 10 and 11) presented falsepositive results on dual-phase BSGI, and they had five benign lesions (1 hamartoma, 3 FCCs and 1 intraductal papilloma). There were three false-negative BSGI results. All three patients underwent an ultrasound-guided core needle biopsy, and the pathological results included two DCIS foci (0.1 cm and 0.6 cm), one LCIS (1.1 cm) and one low-grade IDC (1.1 cm) (one patient had both DCIS and IDC). One patient who had both low-grade DCIS and low-grade IDC was classified as group 2, and tracer washout was shown on the patient's delayed images. Delayed images were not available for the remaining two patients because their early images were classified as group 1 (definite negative).
Diagnostic Performance of Single-and Dual-Phase Imaging
The results and diagnostic performance of single-and dualphase BSGI for breast cancer detection are shown in Tables 3  and 4 in a patient-based analysis. Using dual-phase imaging, the false-positive rate of BSGI decreased from 18 % (11/63) to 5 % (3/63), and the positive predictive value increased from 48 % to 75 %. The specificity of BSGI was significantly higher with dual-phase imaging than with singlephase imaging (p00.0078), but there was no significant difference in sensitivity.
Scintigraphic Findings of Patients with US BI-RADS 4
Using the US BI-RADS classification system, 1 patient was classified as category 0, 1 was classified as category 1, 18 were classified as category 2 and 22 were classified as category 3. There were 41 category 4 lesions in 32 patients. Three patients had a category 5 lesion, and 1 patient had a category 6 lesion.
All of the 32 patients with BI-RADS category 4 lesions underwent biopsies to confirm the pathological diagnosis. The pathological and dual-phase BSGI results are shown in Table 5 . There were five false-negative lesions and five false-positive lesions with dual-phase BSGI (Table 6) .
Based on dual-phase imaging, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of BSGI for the evaluation of US BI-RADS category 4 lesions were 60 %, 86 %, 67 %, 83 % and 78 %, respectively. 
Discussion
Scintimammography is the functional imaging study of the breast. Several single-site and multicenter studies have demonstrated that scintimammography has improved specificity compared to mammography. The limitations of scintimammography performed with general-purpose gamma cameras did not allow for the reliable detection of small lesions (< 1 cm) [11] [12] [13] . In a meta-analysis by Lieberman, the overall sensitivity and specificity were 85.2 % and 86.6 %, respectively, in a total of 5,340 patients assessed for breast cancer with scintimammography. For patients with a palpable mass, the sensitivity and specificity were 87.8 % and 87.5 %, respectively. For patients without a palpable mass, the sensitivity was 66.8 %, and the specificity was 86.9 % [13] .
To overcome the limitations of a general-purpose gamma camera for the detection of breast cancer, a high-resolution, small field of view breast-specific gamma camera was developed. This technique is referred to as breast-specific gamma imaging (BSGI) [11, 12, 14] . Studies with BSGI have demonstrated the reliable detection of small cancerous lesions, including invasive and ductal carcinoma in situ (DCIS) as small as 1 mm [8, [15] [16] [17] . Furthermore, the BSGI camera allows for imaging in positions comparable to Fig. 4 A 52-year-old woman with a previous history of surgical excision for intraductal papillomatosis. a Breastspecific gamma imaging. Early images (MLO and CC view) reveal mild and nodular radioactivity (arrow) in the right breast (arrow). This case was classified as group 3 (possible positive). A delayed image obtained 1 h after tracer injection shows tracer washout in the area. b Ultrasonography. The image shows a hypoechoic lesion (0.7 cm) with a partially indistinct margin in the right breast at the 10 o'clock position (BI-RADS category 4A). Pathology from a core-needle biopsy showed a fibroadenoma mammography, which allows for a more direct correlation of mammographic imaging and BSGI [18] . The use of high-resolution, small field of view breastspecific gamma imaging (BSGI) has been shown to increase the sensitivity of nuclear breast imaging [9, 16, 19] . The sensitivity of BSGI ranges from approximately 78 % to 100 % for detecting breast cancer. The reported specificities of BSGI range from 59 % to 93 % [8-10, 14-18, 20] . In our study, using early images, the sensitivity and specificity were 77 % and 83 %, respectively, which were similar to those identified by previous studies. Brem et al. [8] reported that the PPV and NPV of BSGI were 68.8 % and 94.3 %, respectively, in a setting of 49.7 % disease prevalence. In our study, using early images, the PPV and NPV were 48 % and 95 %, respectively, in a setting of 17.1 % disease prevalence.
Brem et al. [8] evaluated 146 patients and showed a higher overall sensitivity (96.4 %) than previously reported BSGI studies. They suggested that one of the reasons for their high sensitivity was the early onset of imaging because patients in their study were imaged immediately after 99m Tcsestamibi injection, whereas the patients in the prior BSGI studies were imaged 1-1.5 h after injection. They proposed that delayed imaging (1-1.5 h) might have decreased the sensitivity because of increased 99m Tc-sestamibi washout from the cancer. In our study, using dual-phase imaging, the sensitivity was decreased from 77 % to 69 %, but there was no significant difference between early and dual-phase imaging (p01.0). However, the specificity, PPV and accuracy were increased using dual-phase compared to early imaging, and there was a significant difference in the specificity.
Dual-phase imaging in BSGI is based on the assumption that 99m Tc-sestamibi uptake by cancerous cells might persist on delayed images compared with benign conditions. Dualphase imaging could help to discriminate between benign and malignant lesions in breast tissue. In their preliminary study on palpable lesions, Cho et al. [21] suggested that delayed imaging had value in increasing the specificity of BSGI to determine breast lesions. They evaluated 19 breast cancer patients with 23 palpable lesions (18 malignant lesions and 5 benign lesions) using early (10 min) and delayed (30 min) double-phase, dedicated, high-resolution scintimammography using 99m Tc-MIBI. They showed 100 % sensitivity and 60 % specificity for the evaluation of palpable breast lesions based on early images, and using short-interval delayed imaging (30 min) was useful for increasing the specificity from 60 % to 100 %. Two lesions showed increased 99m Tc-sestamibi uptake on early images and a decrease in uptake on delayed images. Both lesions were confirmed as benign using histopathology.
To our knowledge, this is the first study investigating the usefulness of the addition of 1-h delayed imaging in BSGI to detect breast cancer among patients with palpable or nonpalpable breast lesions. Our study demonstrated that the use of dual-phase imaging increased the specificity of BSGI from 83 % to 95 % (p00.0078). Although a statistical analysis was not performed, the results showed that the addition of delayed imaging increased the PPV from 48 % to 75 % and the accuracy from 82 % to 91 %.
Delayed imaging was particularly helpful for patients who had lesions with asymmetrically mild and nodular tracer uptake on early images (group 3 in this study). In these cases, the BSGI diagnoses were changed from malignant to benign for nine patients (9/10, 90 %) using dualphase imaging. In these nine patients, there was only one false-negative case, and the pathologic result was DCIS. Moreover, the radiological findings of most patients in group 3 were regarded as physiological parenchymal activity. This is important for health screening because it reduces equivocal results.
Dual-phase imaging would be helpful to reduce falsepositive BSGI results. Fibroadenomas, fibrocystic disease and inflammatory lesions are well-known causes of false- Tc-sestamibi uptake, and they compromise the specificity of scintimammography [21] . In this study, there were 11 false-positive BSGI results, and they included patients with FCC, fibroadenoma, intraductal papilloma and hamartoma. Of the 11 false positives, nine patients showed tracer washout 1 h after tracer injection (9/11, 82 %).
The identification of breast lesions on BSGI can be limited by the size and aggressiveness of the tumor [12] . In our study, there were three false-negative BSGI results (4 lesions). The pathological results included two DCIS foci (0.1 cm and 0.6 cm), one LCIS (1.1 cm) and one low-grade IDC (1.1 cm). A previous study reported BSGI sensitivities of approximately 92 % for lesions >1 cm and 67 % for lesions <1 cm, and tumors as small as 0.3 mm were detected [9] . Ductal cancers of the highest grade (grade III) show the highest uptake of 99m Tc-sestamibi, while lobular cancers show the lowest uptake or even no uptake. In this manner, 99m Tc-sestamibi uptake reflects tumor aggressiveness [13, 22] .
Ultrasonography has emerged as the most important adjunct to mammography in the diagnosis of breast diseases. BI-RADS category 4 is used to stratify a wide range of lesions recommended for biopsy [23] . In our study, there were 32 patients with 41 US BI-RADS category 4 lesions. In these patients, 4 of the 15 lesions (27 %) in groups 3 and 4 showed washout on dual-phase imaging (Table 5 ). Based on dual-phase imaging, the specificity, negative predictive value and accuracy were 87 %, 84 % and 78 %, respectively. The SNM Practice Guideline for Breast Scintigraphy with Breast-Specific Gamma Cameras includes interpretation criteria using BI-RADS classification. In the criteria, small focal areas of increased uptake in the breast or axilla (in the absence of radiopharmaceutical infiltration) represent an equivocal result, which is consistent with malignancy, inflammation, atypia or fat necrosis, and are classified as BI-RADS category 4 [24] . According to our results, dual-phase imaging would be helpful to reduce false-positive BSGI results, and the use of delayed washout for breast lesion assessment may help to reduce equivocal diagnoses.
There were limitations to our study. First, this study was retrospective in design. Second, it had a small sample size. Third, pathological confirmation was not performed on all patients with an abnormality identified using BSGI. In this study, patients with lesions with abnormal findings identified using BSGI and definitive benign findings identified using both mammography and ultrasonography did not undergo a biopsy. Instead, careful imaging follow-up studies were performed in these patients after at least 6 months. Fourth, immunohistochemical staining for p-glycoprotein, which is known as a regulator of MIBI accumulation in malignant tumors, was not performed.
In conclusion, dual-phase imaging in BSGI had good diagnostic performance and would be useful for increasing interpreter diagnostic confidence, with higher specificity, positive predictive value and accuracy for breast cancer screening as well as the differential diagnosis of breast disease compared with single-phase imaging. However, it could not replace or reduce biopsies for US BI-RADS category 4 lesions because of false-positive results for small or low-grade malignant lesions. (1) 0
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